| Similar Articles |
|---|
 |
BusinessWeek
December 13, 2004
Bruce Einhorn |
Go East, Big Pharma Drugmakers are expanding in China, but patents are still a worry.   |
Chemistry World
September 17, 2007 |
Uk Pharma Shifts Manufacturing Overseas Drug firm AstraZeneca has today reiterated that it will outsource drug manufacturing. |
The Motley Fool
May 26, 2006
Brian Gorman |
AstraZeneca's Essential Investment The drugmaker seems to be jumping on the China bandwagon, but its investment makes sense, given the potential return. |
The Motley Fool
July 30, 2007
Brian Lawler |
AstraZeneca's Yawner of a Quarter The pharma's second-quarter results are ho-hum. Investors may do well to take a look at some of the other big pharma stocks, which offer more compelling reasons to buy. |
Chemistry World
July 15, 2008
Hepeng Jia |
Testing Times for New Liver Drug AstraZeneca is set to start clinical trials of a liver cancer drug developed for Chinese patients. |
The Motley Fool
December 27, 2007
Brian Orelli |
Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there. |
The Motley Fool
November 12, 2009
Brian Orelli |
How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way. |
Financial Advisor
July 2009
Jeff Schlegel |
Rebuilding With BRICs The Big Four of emerging markets are back in favor. |
BusinessWeek
January 21, 2010
John Lee |
Don't Underestimate India's Consumers Western multinationals are often attracted to China's size, but they're bypassing Asia's true shopping powerhouse |
The Motley Fool
July 30, 2010
Cliff D'Arcy |
Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline. |
Pharmaceutical Executive
September 1, 2008
Patrick Clinton |
Attack of the Junk The United States makes the best medicines in the world. In days to come, that could be a problem. |
The Motley Fool
April 26, 2007
Brian Lawler |
AstraZeneca's Announcement Overshadows Earnings AstraZeneca releases first-quarter financial results. Investors, take note. |
Pharmaceutical Executive
December 1, 2010
Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
Chemistry World
June 5, 2009
Anna Lewcock |
Pharma's new world order So-called 'pharmerging' markets will contribute over half of the growth of the global pharmaceutical market this year, according to market analysts. |
The Motley Fool
April 24, 2007
Brian Lawler |
MedImmune Not Immune to Takeovers MedImmune shops itself to AstraZeneca. MedImmune investors appear to be getting a pretty sweet deal. |
Search Engine Watch
May 4, 2011
Andy Atkins-Kruger |
Should Google Escape the Death Spiral in China by 'Losing Face'? Weighing which of four paths Google should take when it comes to China: promote within China but remain in Hong Kong; do something completely different; re-enter China; or do nothing. |
Chemistry World
December 20, 2013
Patrick Walter |
AstraZeneca shells out $4.1bn for diabetes business AstraZeneca has agreed to pay Bristol-Myers Squibb up to $4.1 billion for its share of the pharma giants' diabetes joint venture. |
The Motley Fool
July 6, 2009
Nathan Parmelee |
China's Getting Old Fast According to an article in last week's The Economist, which references United Nations data on aging trends, China can expect to see an ever-greater portion of retirees dominate its population. And health-care spending should soar. |
Chemistry World
December 24, 2015
Jennifer Newton |
AstraZeneca to buy Acerta for blood cancer drug AstraZeneca has agreed to buy a majority stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US. |
IndustryWeek
September 1, 2008
David Blanchard |
Eye On China As China rapidly evolves into a more service-oriented economy, U.S. manufacturers need to adjust their China strategy to remain competitive. |
The Motley Fool
April 24, 2007
Brian Lawler |
AtheroGenics Loses a Partner The specialty drug maker's drug-development partner bails. Waiting around for years on more clinical trial results for a drug with such unproven efficacy is not something that is a recipe for success with specialty pharma stock investing. |
Chemistry World
December 2006
Derek Lowe |
Opinion: In the Pipeline A look at the story behind the growing investment by western companies in medicinal chemistry research in China. |
Chemistry World
February 2, 2012
Andrew Turley |
AstraZeneca to cut 7300 more jobs UK drugmaker AstraZeneca has announced plans to cut a further 7300 jobs to make annual savings of $1.6 billion by the end of 2014, a move that will cost the company $2.1 billion in the near term. |
The Motley Fool
July 11, 2007
Brian Lawler |
Not All Pharmaceutical Markets Are the Same The case of China's former FDA leader highlights the issues facing the country's pharmaceutical industry. Investors, take note. |
The Motley Fool
August 14, 2008
Todd Wenning |
Time for a Rebound in China With China shares down big this year, now's the time to consider investing. |
BusinessWeek
August 4, 2003
Bruce Einhorn |
Outsourcing: Make Way for China It's fast becoming an important hub for IT services. Move over, India. |
AFP eWire
June 10, 2014
Melody Song |
Philanthropy in China In consideration of China's special relationship with our country, Canada's nonprofit sector should consider market specific strategy for fundraising success to engage Chinese philanthropists |
The Motley Fool
June 30, 2010
Anders Bylund |
Google Blew Its Chances in China After thumbing its nose at Chinese censorship this winter, Google is now at risk to lose its online business license in China outright. |
BusinessWeek
May 5, 2011
Peter Coy |
The Case for Making It in the USA Rising wages in China and high productivity in the U.S. may prompt more companies to keep manufacturing in America. |
BusinessWeek
October 27, 2003 |
The BRICs Are Coming -- Fast A Goldman economist talks about rapid growth in Brazil, Russia, India, and China |
The Motley Fool
October 20, 2011
Brad Hessel |
Forget the BRICs; Here's a Better Way to Think About Emerging Markets Who are the new emerging market countries?: China, Russia, Brazil, India, South Korea and Mexico. Or McRIBS for short. |
The Motley Fool
February 9, 2007
Will Frankenhoff |
I Love Chinese Stocks Given the overall strength of the Chinese economy and the attractive valuations of many "red-chip" companies, investors should consider opening their hearts to this emerging market's potential rewards, and adding to their positions during any weakness. |
Pharmaceutical Executive
April 1, 2006
Ron Feemster |
Thought Leader: Q&A with Joel A. Tune Pharma still enlists contract manufacturers as safety valves, but today's drug developers have also begun to outsource the production of increasingly complicated compounds while they are still in clinical trials. |
The Motley Fool
August 3, 2010
Dan Dzombak |
3 Lifeboat Stocks Stop your portfolio from sinking with Big Pharma and Big Oil. |
Chemistry World
January 11, 2013
Andrew Turley |
Pharma industry 'strategic crisis' The pharma industry is grappling with a 'strategic crisis' according to three quarters of companies surveyed in a report from consultancy firm Roland Berger. |
Pharmaceutical Executive
March 1, 2013 |
China and the Emerging Markets Challenge: Why Big Pharma Must Embrace a New Strategy With health reform already tagged as a key domestic priority, their policies will pose new opportunities and challenges for Big Pharma companies active in China. |
The Motley Fool
July 12, 2010
Eric Jhonsa |
Tech Stocks That Could Fall Victim to Currency Mayhem A plunging euro and a rising yuan could spell trouble for some big tech names. |
BusinessWeek
November 6, 2006
Bruce Einhorn |
A Dragon In R&D China's labs may soon rival its powerhouse factories - and multinationals are flocking in for tech innovation. |
The Motley Fool
March 10, 2009
Dan Caplinger |
The Brightest Beacon in a Gloomy World Investors fled from the emerging economies in the wake of financial troubles throughout the developed world. This year some of those economies have seen their stocks finally recover somewhat. |
BusinessWeek
February 3, 2011
Thomasson & Nazareth |
Chinese Stocks Look Ready to Rally The MSCI China Index hit a record low compared with Hong Kong stocks |
Chemistry World
December 20, 2013
Patrick Walter |
Chinese police seize 222m pounds of fake drugs Counterfeit medicines and raw materials worth more than Yuan2.2 billion have been seized by Chinese authorities. |
| Knowledge@Wharton |
Shanghai and Hong Kong: China's Twin Engines of Growth China's economy will be like a giant 747 with Shanghai and Hong Kong acting as its two main engines, if Hong Kong can reinvent itself to balance Shanghai's growing prosperity, according to Ming K. Chan, an authority on Hong Kong and Asian development. |
BusinessWeek
June 2, 2011
Kresge & Connolly |
A New Pricing Game for Drugmakers in Europe Germany's new rules tying pharmaceutical prices to greater efficacy is worrying companies. |
Chemistry World
February 2, 2007
Victoria Gill |
AstraZeneca Follows Pfizer in Slashing Workforce The Anglo-Swedish pharmaceutical hopes that by streamlining its operation it can offset the growing financial threat from cheap generic copies of its best-selling blood pressure drug. Nevertheless, the company has reported unexpectedly cheerful fourth quarter profits. |
Pharmaceutical Executive
October 1, 2006
Ray Hill |
China: Big Rewards. Bigger Risks? The world's fastest growing pharmaceutical market may one day be the largest. Breaking in could be industry's greatest challenge. |
IndustryWeek
January 1, 2004
John S. McClenahen |
Expanding The Discovery Channel Additional R&D labs at AstraZeneca in Waltham, Mass., promise to aid in development of cancer and infectious disease drugs. |
Chemistry World
November 22, 2010
Akshat Rathi |
Irish drug industry fears bailout tax terms Any increase in Ireland's corporation tax rate as part of a financial bailout could hurt the country's rapidly expanding pharmaceutical industry, currently its largest contributor to corporation tax. |
BusinessWeek
March 4, 2010
Frederik Balfour |
The Ka-Ching in China Luring Medical Giants GE, Siemens, and others are angling for a piece of the $125 billion Beijing plans to spend on health care. |
Pharmaceutical Executive
July 3, 2007 |
Thought Leader: Connected Markets, Rob Dhoble It used to be that pharma companies had one marketing strategy for the US and other developed nations, a second strategy for emerging countries, and a third, mostly focused around access, for the developing world. But in a global environment, that doesn't work. |
InternetNews
March 23, 2010 |
Chinese Official Says Google 'Totally Wrong' A Chinese official speaking to state-run news service blasts Google's plan to offer an unfiltered Web to mainland residents by redirecting traffic to its Hong Kong search engine. |
